425 related articles for article (PubMed ID: 23816773)
1. Impact of metastatic colorectal cancer stage and number of treatment courses on patient health care costs and utilization.
Chastek B; Kulakodlu M; Valluri S; Seal B
Postgrad Med; 2013 Mar; 125(2):73-82. PubMed ID: 23816773
[TBL] [Abstract][Full Text] [Related]
2. Medical costs associated with use of systemic therapy in adults with colorectal cancer.
Seal BS; Sullivan SD; Ramsey S; Shermock KM; Ren J; Kreilick C; Foltz Boklage SH; Valluri S; Sarma S; Asche CV
J Manag Care Pharm; 2013; 19(6):461-7. PubMed ID: 23806060
[TBL] [Abstract][Full Text] [Related]
3. Trends in healthcare utilization among older Americans with colorectal cancer: a retrospective database analysis.
Lang K; Lines LM; Lee DW; Korn JR; Earle CC; Menzin J
BMC Health Serv Res; 2009 Dec; 9():227. PubMed ID: 20003294
[TBL] [Abstract][Full Text] [Related]
4. The economic burden of lung cancer and the associated costs of treatment failure in the United States.
Kutikova L; Bowman L; Chang S; Long SR; Obasaju C; Crown WH
Lung Cancer; 2005 Nov; 50(2):143-54. PubMed ID: 16112249
[TBL] [Abstract][Full Text] [Related]
5. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.
Maddux FW; Shetty S; del Aguila MA; Nelson MA; Murray BM
Ann Pharmacother; 2007 Nov; 41(11):1761-9. PubMed ID: 17895328
[TBL] [Abstract][Full Text] [Related]
6. Patterns of Medical Care Cost by Service Type for Patients With Recurrent and De Novo Advanced Cancer.
Banegas MP; Hassett MJ; Keast EM; Carroll NM; O'Keeffe-Rosetti M; Fishman PA; Uno H; Hornbrook MC; Ritzwoller DP
Value Health; 2022 Jan; 25(1):69-76. PubMed ID: 35031101
[TBL] [Abstract][Full Text] [Related]
7. Healthcare costs in patients with metastatic lung cancer receiving chemotherapy.
Vera-Llonch M; Weycker D; Glass A; Gao S; Borker R; Barber B; Oster G
BMC Health Serv Res; 2011 Nov; 11():305. PubMed ID: 22074001
[TBL] [Abstract][Full Text] [Related]
8. Neutropenia-related costs in patients treated with first-line chemotherapy for advanced non-small cell lung cancer.
Stokes ME; Muehlenbein CE; Marciniak MD; Faries DE; Motabar S; Gillespie TW; Lipscomb J; Knopf KB; Buesching DP
J Manag Care Pharm; 2009 Oct; 15(8):669-82. PubMed ID: 19803556
[TBL] [Abstract][Full Text] [Related]
9. Real-World Costs of Adverse Events in First-Line Treatment of Metastatic Non-Small Cell Lung Cancer.
Engel-Nitz NM; Johnson MP; Bunner SH; Ryan KJ
J Manag Care Spec Pharm; 2020 Jun; 26(6):729-740. PubMed ID: 32463768
[TBL] [Abstract][Full Text] [Related]
10. Healthcare utilization and costs associated with COPD among SEER-Medicare beneficiaries with NSCLC.
Shah S; Blanchette CM; Coyle JC; Kowalkowski M; Arthur ST; Howden R
J Med Econ; 2018 Sep; 21(9):861-868. PubMed ID: 29857784
[TBL] [Abstract][Full Text] [Related]
11. Patient Characteristics and Costs in Recurrent or Refractory Head and Neck Cancer: Retrospective Analysis of a Community Oncology Database.
Fisher MD; Fernandes AW; Olufade TO; Miller PJ; Walker MS; Fenton M
Clin Ther; 2018 Apr; 40(4):562-573. PubMed ID: 29530457
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of trends in the cost of initial cancer treatment.
Warren JL; Yabroff KR; Meekins A; Topor M; Lamont EB; Brown ML
J Natl Cancer Inst; 2008 Jun; 100(12):888-97. PubMed ID: 18544740
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of new and emerging treatment options for the treatment of metastatic colorectal cancer.
Zadlo J
Am J Manag Care; 2018 Apr; 24(7 Suppl):S118-S124. PubMed ID: 30207664
[TBL] [Abstract][Full Text] [Related]
14. Differences in survival for patients with metastatic colorectal cancer by lines of treatment received and stage at original diagnosis.
Seal B; Chastek B; Kulakodlu M; Valluri S
Int J Clin Pract; 2015 Feb; 69(2):251-8. PubMed ID: 25302640
[TBL] [Abstract][Full Text] [Related]
15. Health care resource utilization and costs associated with advanced or metastatic nonsmall cell lung cancer in the United States.
Zhang X; Beachler DC; Masters E; Liu F; Yang M; Dinh J; Jamal-Allial A; Kolitsopoulos F; Lamy FX
J Manag Care Spec Pharm; 2022 Feb; 28(2):255-265. PubMed ID: 34854733
[No Abstract] [Full Text] [Related]
16. Costs of care associated with non-small-cell lung cancer in a commercially insured cohort.
Hillner BE; McDonald MK; Desch CE; Smith TJ; Penberthy LT; Maddox P; Retchin SM
J Clin Oncol; 1998 Apr; 16(4):1420-4. PubMed ID: 9552046
[TBL] [Abstract][Full Text] [Related]
17. Cost drivers for breast, lung, and colorectal cancer care in a commercially insured population over a 6-month episode: an economic analysis from a health plan perspective.
Sagar B; Lin YS; Castel LD
J Med Econ; 2017 Oct; 20(10):1018-1023. PubMed ID: 28581874
[TBL] [Abstract][Full Text] [Related]
18. Administrative claims analysis of all-cause annual costs of care and resource utilization by age category for ulcerative colitis patients.
Bickston SJ; Waters HC; Dabbous O; Tang BI; Rahman M
J Manag Care Pharm; 2008 May; 14(4):352-62. PubMed ID: 18500913
[TBL] [Abstract][Full Text] [Related]
19. Direct economic burden of high-risk and metastatic melanoma in the elderly: evidence from the SEER-Medicare linked database.
Davis KL; Mitra D; Kotapati S; Ibrahim R; Wolchok JD
Appl Health Econ Health Policy; 2009; 7(1):31-41. PubMed ID: 19558193
[TBL] [Abstract][Full Text] [Related]
20. Health care utilization and costs by site of service for nonmetastatic breast cancer patients treated with trastuzumab.
Parthan A; Santos E; Becker L; Small A; Lalla D; Brammer M; Teitelbaum A
J Manag Care Spec Pharm; 2014 May; 20(5):485-93. PubMed ID: 24761820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
